Patents Assigned to Berlin-Chemie AG
-
Publication number: 20220289851Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.Type: ApplicationFiled: May 3, 2022Publication date: September 15, 2022Applicant: BERLIN-CHEMIE AGInventors: Monica BINASCHI, Mario BIGIONI, Giuseppe MERLINO, Cecilia SIMONELLI, Francesco BERTONI, Andrea PELLACANI
-
Patent number: 11365258Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.Type: GrantFiled: March 9, 2018Date of Patent: June 21, 2022Assignee: BERLIN-CHEMIE AGInventors: Monica Binaschi, Mario Bigioni, Giuseppe Merlino, Cecilia Simonelli, Francesco Bertoni, Andrea Pellacani
-
Publication number: 20210113690Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) Venetoclax; methods for preparing pharmaceutical combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.Type: ApplicationFiled: June 13, 2019Publication date: April 22, 2021Applicant: BERLIN-CHEMIE AGInventors: Giuseppe MERLINO, Mario BIGIONI, Monica BINASCHI, Andrea PELLACANI
-
Publication number: 20210032360Abstract: The present disclosure relates to methods of preventing or treating myelodysplastic syndrome (MDS) using antibodies or antigen-binding portions thereof directed against BST1.Type: ApplicationFiled: April 12, 2019Publication date: February 4, 2021Applicant: BERLIN-CHEMIE AGInventors: Daniela BELLAROSA, Corrado CARRISI, Andrea PELLACANI, Chirstian ROHLFF, James Edward ACKROYD, Monica BINASCHI
-
Publication number: 20210015826Abstract: The present invention relates to new combinations of antitumour or anticancer agents for the tumour combination therapy, pharmaceutical compositions intended for combined use and kit containing compositions of different antitumour agents for combined use. In particular the present invention relates to combinations of various tumour agents with the PBK-Class I inhibitor 5-(7-methanesulfonyl-2-morpholin-4-yl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)-pyrimidin-2-il-amine or pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 28, 2019Publication date: January 21, 2021Applicant: BERLIN-CHEMIE AGInventors: Giuseppe MERLINO, Mario BIGIONI, Monica BINASACHI, Andrea PELLACANI
-
Publication number: 20200231694Abstract: The disclosure relates to pharmaceutical combinations comprising antibodies against BST1 (ADP-ribosyl cyclase 2) together with a cytidine analogue or a pharmaceutically-acceptable salt thereof, and methods for the treatment of diseases, such as cancers mediated by BST1 (ADP-ribosyl cyclase 2) expression/activity and/or associated with abnormal expression/activity of BST1.Type: ApplicationFiled: July 20, 2018Publication date: July 23, 2020Applicant: BERLIN-CHEMIE AGInventors: Cecilia SIMONELLI, Andrea PELLACANI, Monica BINASCHI, Daniela BELLAROSA, Corrado CARRISI
-
Publication number: 20200040086Abstract: The present disclosure relates generally to the fields of immunology and molecular biology. More specifically, provided herein are pharmaceutical combinations comprising (A) antibodies, or antigen-binding portions thereof, directed against LY75, and (B) a second anti-cancer entity; nucleic acids encoding antibody combinations; methods for preparing antibody combinations; and methods for the treatment of diseases, such as cancers mediated by LY75 expression or activity.Type: ApplicationFiled: September 3, 2018Publication date: February 6, 2020Applicant: BERLIN-CHEMIE AGInventors: Monica BINASCHI, Mario BIGIONI, Giuseppe MERLINO, Cecilla SIMONELLI, Francesco BERTONI
-
Patent number: 6864366Abstract: Process of preparing (E)-5-(2-bromovynyl)-2?-deoxyuridine (Brivudine) characterized in that halogen-free solvent selected form esters or cyclic ethers are used in the bromination step of 5-ethyl-2?-deoxyuridine diacylate. The use of solvents is advantageous in respect of toxicity, discharge costs and environment protection.Type: GrantFiled: February 21, 2002Date of Patent: March 8, 2005Assignees: Menarini Richerche S.p.A., Berlin-Chemie AGInventors: Aldo Salimbeni, Carlo Alberto Maggi, Stefano Manzini, Damiano Turozzi
-
Patent number: 5656601Abstract: The invention relates to new compounds of acylated splenopentins of Formula IR.sup.1 -arg-lys-(R.sup.2)-glu-val-tyr(R.sup.3)R.sup.4 Iwherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 are as defined in the specification, methods for their synthesis by acylation of splenopentins, as well as to their use as pharmacologically active peptides which are suitable for normalizing the function of the immunological system in primary and secondary immunological deficiencies.Type: GrantFiled: June 20, 1991Date of Patent: August 12, 1997Assignee: Berlin-Chemie AGInventors: Klaus Forner, Angelika Ehrlich, Wolfgang Diezel, Rolf Eckert, Elke Euthin, Eberhard Krause, Peter Slonina, Hans-Dieter Volk, Heinrich Repke, Monika Georgi, Martina Leidert, Michael Bienert, Michail Ovcinnikov, Ralph Schmidt, Manfred Schuett, Renate Mentel, Winfried Breustedt
